bedaquiline (Sirturo)
Jump to navigation
Jump to search
Indications
- pulmonary tuberculosis, as component of combination therapy for adults with multi-drug resistant tuberculosis, when no satisfactory alternatives remain
Dosage
- directly observed oral therapy[6]
Storage:
- can be dispensed in original container, or a tight, light-resistant container
- must be used within 3 months if stored in a container other than the original[5]
Adverse effects
Laboratory
Mechanism of action
- enzyme inhibitor
- inhibits Mycobacterial ATP synthase[6]
More general terms
References
- ↑ FDA Newe Release: Dec. 31, 2012 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm
- ↑ World Health Oragnization (WHO). 2013 The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim Policy Guideline. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf
World Health Oragnization (WHO). 2013 WHO interim guidance on the use of bedaquiline to treat MDR-TB https://mail.google.com/mail/u/0/?shva=1#inbox/13f425db09d8dfc1 - ↑ Mase S et al Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis. MMWR. October 25, 2013 / 62(rr09);1-12 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6209a1.htm
- ↑ Deprecated Reference
- ↑ 5.0 5.1 Prescriber's Letter 21(6): 2014 Oral Meds to Keep in Original Containers Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300622&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 6.0 6.1 6.2 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015